Skip to main content
Toggle navigation
Products
Technology Overview
The FoldX Suite
FoldX
LoopX
PepX
BackX
DnaX
InterpretiX
YasaraPg
Publications
Licensing and Services
Products Features Comparison
Academic License
Evaluation License
Commercial License
Services and Training
Documentation
Manual
FAQ
Fixes
Download
Academic License
Commercial License
About
Consortium
News
aknowledgements
Contact Us
Login
Register
In silico engineering a CD80 variant with increased affinity to CTLA-4 and decreased affinity to CD28 for optimized cancer immunotherapy.
Submitted by
Javi
on Fri, 05/05/2023 - 15:07
